Skip to main content
WV

Wave View Imaging Inc.

Wave View Imaging develops a portable, non-ionizing ultra-wideband (UWB) imaging device for breast health monitoring. This technology measures the electrical properties of breast tissues to create images for improved tumor detection and treatment monitoring at the point-of-care. The system offers a comfortable, fast, and simple alternative to traditional mammography, enabling frequent scanning across various clinical settings.

Calgary, CanadaFounded 202010500+ followers
Updated 20 months ago

Funding

Funding not disclosed

PA
Funding rounds are not available yet.

Founders

Product

Problem

Current breast cancer screening methods can be uncomfortable, costly, and may not be suitable for frequent use or for women of all ages and breast densities. Existing technologies may also lack the ability to effectively monitor tumor response during treatment, hindering timely adjustments to care plans.

Solution

Wave View Imaging is developing a non-invasive breast imaging device that uses ultra-wideband (UWB) signal technology to measure breast tissue properties. The device detects tumors based on their distinct electrical characteristics, providing timely information on breast density and tumor response during treatment. The technology offers a comfortable and safe alternative for frequent breast health monitoring, suitable for women at any age. The device provides physicians with supporting data to guide recommendations for further screening and to help adapt cancer treatments as needed.

Target Audience

The primary target audience includes physicians, radiologists, and breast cancer specialists seeking a comfortable, safe, and affordable breast imaging solution, as well as women of all ages seeking frequent and non-invasive breast health monitoring.

Features

  • Non-intrusive UWB signal technology measures breast tissue properties.
  • Detects tumors based on differences in electrical properties compared to healthy tissues.
  • Provides breast density scores, a known risk factor for breast cancer.
  • Assesses response to neoadjuvant treatment within days of treatment initiation.
  • Tabletop scanning with a small footprint.
  • Simple to use and not operator dependent.
  • Low power electromagnetic signal, much less than a cellphone.
  • 2D image reconstruction of electrical properties displayed in seconds.
This profile is AI-generated and may contain inaccuracies.